GLS and neoplasm: In an attempt to leverage increased tumor-cell reliance on glutamine, small molecule inhibitors of GLS1 were developed (e.g., bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), CB-839, compound 968) [10–12].